You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

CLINICAL TRIALS PROFILE FOR EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02345226 ↗	Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppresse	Completed	Gilead Sciences	Phase 3	2015-01-26	The primary objective of this study is to evaluate the non-inferiority of switching to emtricitabine/rilpivirine/tenofovir alafenamide (FTC/RPV/TAF) fixed dose combination (FDC) as compared to continuing the non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen of efavirenz /FTC/tenofovir disoproxil fumarate (EFV/FTC/TDF) FDC in virologically-suppressed HIV-1 infected participants.
NCT02345252 ↗	Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxi	Completed	Gilead Sciences	Phase 3	2015-01-26	The primary objective of this study is to evaluate the noninferiority of switching to emtricitabine/rilpivirine /tenofovir alafenamide (FTC/RPV/TAF) fixed-dose combination (FDC) as compared to continuing FTC/RPV/tenofovir disoproxil fumarate (TDF) FDC (FTC/RPV/TDF) in virologically suppressed HIV-1 infected participants.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate

Condition Name

Chart
Table

Condition Name for emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate
Intervention	Trials
HIV-1 Infection	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate
Intervention	Trials
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate

Trials by Country

Map
Table

Trials by Country for emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate
Location	Trials
United States	50
Canada	9
Germany	4
Belgium	2
Puerto Rico	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate
Location	Trials
Florida	2
District of Columbia	2
Connecticut	2
Colorado	2
California	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate
Clinical Trial Phase	Trials
Phase 3	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate
Clinical Trial Phase	Trials
Completed	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate

Sponsor Name

Chart
Table

Sponsor Name for emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate
Sponsor	Trials
Gilead Sciences	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate
Sponsor	Trials
Industry	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.